NCT05075304View on ClinicalTrials.gov

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 21, 2020

Primary Completion Date

April 14, 2020

Study Completion Date

April 14, 2020

Conditions
COVID-19
Interventions
DRUG

BDB-001 injection

IV infusions of Injection diluted in sodium chloride

DRUG

BDB-001 injection

IV infusions of Injection diluted in sodium chloride

DRUG

BDB-001 injection

IV infusions of Injection diluted in sodium chloride

Trial Locations (4)

310022

Shu Lan (Hangzhou) Hospital, Hangzhou

430060

Renmin Hospital Of Wuhan University Bubei General Hospital, Wuhan

430070

General Hospital of Gentral Rheater Command, Wuhan

572000

Sanya Central Hospital (Hainan Third People'S Hospital), Sanya

Sponsors
All Listed Sponsors
collaborator

Beijing Defengrui Biotechnology Co. Ltd

UNKNOWN

lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY